Advances in the Treatment of Acute ITP

Source:
By:Yuheng Jiang, Jiahao Gu, Zai Gu, Yifeng Xu, Bin Jia, Jing Yang

DOI: https://doi.org/10.30564/jim.v11i1.4691

Abstract:

Immune thrombocytopenia (ITP), also known as idiopathic thrombocytopenic purpura, is a hematologic disease in which platelet destruction increases and production decreases, mainly mediated by immunity. However, up to now, the pathogenesis of ITP is not clear, which has caused great trouble in treatment. Therefore, this paper intends to review the recent literature on ITP treatment to provide some reference for clinical treatment. This paper combines the evidence of ASH immune thrombocytopenia and the Chinese Guidelines for the Diagnosis and Treatment of Adult primary immune thrombocytopenia (2020 edition). In this paper, the treatment process of ITP was divided into first-line treatment and second-line treatment, and it was concluded that first-line treatment was often used when newly diagnosed with ITP: combination of high-dose dexamethasone and low-dose gamma globulin. However, it should be noted that only 60%-80% of patients responded to first-line treatment, and most of them relapsed during dosing reduction or drug withdrawal. Second-line treatment is recommended in this case. The standard treatment is splenectomy, but due to its uncontrollable nature and side effects, it should be used cautiously. A new treatment approach, thrombogenin receptor agonist, has great development potential, and multidrug combination therapy for ITP has positive clinical significance.

References:

[1] Neunert, C., Terrell, D.R., Arnold, D.M., et al., 2019. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 3(23), 3829-3866. [2] Wang, Y., Wang, Y., Wang, Y., et al., 2020. A study on the diagnosis and treatment of primary immune thrombocytopenia in adults. Chinese Journal of Hematology. 41(08), 617-623. [3] Yang, S.Zh., Chen, B.Q., He, Zh., 2017. Effect of different doses of gamma globulin combined with dexamethasone on idiopathic thrombocytopenic purpura. Journal of Qiqihar Medical College. 38(03), 298-299. [4] Xu, A., 2021. Efficacy analysis of dexamethasone monotherapy or combination therapy in the treatment of primary immune thrombocytopenia. Dalian Medical University. [5] Li, Y., Huang, Q., Wang, Ch., et al., 2016. Efficacy and safety of high-dose dexamethasone combined with recombinant human thrombopoietin in the treatment of 48 adults with severe primary immune thrombocytopenia. Chinese Journal of Hematology. 37(02), 134-137. [6] Cheng, Y., Guo, X.J., Wei, Y.H., 2021. Effect of attripopanethanolamine on platelet transfusion, coagulation function and peripheral blood Th lymphocyte in patients with ITP. Chinese Journal of Medical Engineering. 29(10), 112-114. [7] Chen, S.L., 2021. The clinical effect of methylprednisolone combined with gamma globulin in the treatment of pediatric ITP. Chinese Journal of Medical Research. 19(08), 143-145. [8] Zhao, Y.D., Lai, W.Q., 2021. Effects of gamma globulin combined with hormone on thrombocytopenic purpura in children. Heilongjiang Pharmaceutical. 34(05), 1115-1116. [9] Feng, Zh., Zhong, Q.X., Huang, Q.B., 2017. Effect of recombinant human thrombopoietin gamma-globulin shock combined with glucocorticoid in the treatment of thrombocytopenic purpura. Shanxi Medical Journal. 46(22), 2784-2786. [10] Wang, Y., 2022. Platelet parameters and cytokine changes of different doses of gamma globulin in the treatment of severe ITP in children. Journal of Contemporary Medicine. 28(05), 51-53. [11] He, W.D., Wang, X.X., Shao, Q.G.,, et al., 2022. Treatment of idiopathic thrombocytopenic purpura in children with different doses of gamma globulin combined with glucocorticoid. Chinese Journal of Mathematical Medicine. 35(01),73-75. [12] Yang, L., Li, Y.G., Guan, Y.J., et al., 2011. Effect analysis of gamma globulin combined with dexamethasone in the treatment of children with acute ITP. Medical Theory & Practice. 34(20), 3596-3597. [13] Ducassou, S., Fernandes, H., Savel, H., et al., 2021. Prospective Evaluation of the First Option, Second-Line Therapy in Childhood Chronic Immune Thrombocytopenia: Splenectomy or Immunomodulation. J Pediatr. 231, 223-230. [14] Vianelli, N., Palandri, F., Polverelli, N., et al., 2013. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica. 98(6), 875-880. [15] Haturvedi, S., Arnold, D.M., McCrae, K.R., 2018. Splenectomy for immune thrombocytopenia: down but not out. Blood. 131(11), 1172-1182. [16] Li, X.Y., He, Y., Ruan, Ch.G., 2011. Progress in the treatment of primary immune thrombocytopenia [J]. Chinese Journal of Experimental Hematology. 29(03), 983-987. [17] Provan, D., Arnold, D.M., Bussel, J.B., et al., 2019. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 3(22), 3780-3817. [18] Kim, T.O., Despotovic, J., Lambert, M.P., 2018. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2(4), 454-461. [19] Vianelli, N., Auteri, G., Buccisano, F., et al., 2022. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. Ann Hematol. pp. 1-16. [20] Wang, Sh.Y., Yu, Z.Q., 2020. International journal of blood transfusion and hematology. 43(02), 122-128. [21] Bao, W., Bussel, J.B., Heck, S., et al., 2010. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 116, 4639-4645. [22] Townsley, D.M., Desmond, R., Dunbar, C.E., et a1., 2013. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. Int J Hematol. 98(1), 48-55. [23] Ran, S.Y., 2019. Progress in the study of discontinuation of thrombocytopenin receptor agonists. Journal of Clinical Medical Literature. 6(38), 2-4. [24] Wang, X.J., Zhu, W.M., Tian, P.J., 2011. Efficacy of dexamethasone combined with prednisone in the treatment of chronic ITP. Chin J med. 17(29), 129. [25] Li, Y.Q., 2012.. Efficacy of IVIg combined with glucocorticoid in treatment of idiopathic thrombocytopenic purpura. Chinese Journal of Disability Medicine. 20(5), 19-20. [26] Cines, D.B., Wasser, J., Rodeghiero, F., et a1., 2017. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 102(8), 1342-1351. [27] Qu, M., Zhou, Z.P., 2019. Progress in second-line treatment of immune thrombocytopenia. Labeled Immunoassay and Clinical. 26(10), 1786-1791. [28] Liao, R., Tang, P., Song, J., et al., 2018. Platelet count on preoperative day 1 predicts the long—term responses to laparoseopic splenectomy for Chinese patients with medically refractory idiopathic thrombocytopenic purpura. BMC Surgery. 18, 108. [29] Nyilas, Á., Paszt, A., Simonka, Z., et al., 2015. Laparoscopic splenectomy is a safe method in cases of extremely large spleens. J Laparoendosc Adv Surg Tech A. 25, 212-216. [30] Breuleux, M., Klopfenstein, M., Stephan, C., et al., 1977. Lane HA. HLA class II alleles in Japanese patients with immune thrombocytopenic purpura. Associations with anti—platelet glycoprotein autoantibodies and responses to splenectomy. Tissue Antigens. 97(13), 646-647. [31] Li, Y., 2016. Feasibility and efficacy analysis of laparoscopic splenectomy in patients with low platelet count ITP. Shandong University. [32] Liu, S., 2017. Study on the regulation of FcγRs in chronic ITP by plateletoietin receptor agonist. Shandong University. [33] Schifferli, A., Nimmerjahn, F., Kühne, T., 2019. Immunomodulation in primary immune thrombocytopenia: a possible role of the fc fragment of romiplostim. Front Immunol. 10(1), 1196. [34] Abdela, J., 2019. Current advance in thrombopoietin receptor agonists in the management of thrombocytopenia associated with chronic liver disease: focus on avatrombopag. Clin Med Insights Blood Disord. 12(1), 1179545X19875105. [35] Ghanima, W., Cooper, N., Rodeghiero, F., et al., 2019. Thrombopoietin receptor agonists: ten years later. Haematologica. 104(6), 1112-1123. [36] Bao, J.Zh., Zhao, X.H., Zhou, Y.M., et al., 2018. Efficacy of Shengxueling capsule combined with low-dose glucocorticoid in the treatment of 53 cases of glucohormone-dependent resistance to natural immune thrombocytopenia. Western Modern Chinese Medicine. 31, 5-8. [37] Wu, Q., Yu, Zh.P., Pan, M., 2019. Heiguipi Decoction combined with prednisone tablet in the treatment of ITP. Clinical Drug Research of Pediatric Chinese Medicine. 11(19), 103-105. [38] Xu, X.D., Wu, B., 2019. Treatment of adult immune thrombocytopenia purpura with Traditional Chinese medicine decoction of Nourishing Qi and Nourishing Yin. Hubei Sichuan Journal of Traditional Chinese Medicine. 14(10), 10-13. [39] Han, P., 2019. Clinical study on the treatment of idiopathic thrombocytopenia purpura with the addition and reduction of Liang Xue Xiaoswelling jidu Decoction. New Traditional Chinese Medicine. (5), 47-49. [40] Wan, F., Yang, J.Y., Xu, Y., et al., 2019. Treatment of refractory thrombocytopenia purpura by combination of Traditional Chinese and Western medicine. China Primary Hospital Health Care. 33(7), 91-99. [41] Yang, X.Q., Yu, H.P., Liu, Sh.F., et al., 2019. Clinical efficacy and observation value of Fuketuo combined with Fuzheng Tiaojing Jiedu Decoction in treatment of children with purpura immune thrombocytopenia. Modern Clinical Clinical of Traditional Chinese Medicine. 6, 30-34. [42] Shao, J.B., Ding, J.Y., Li, Sh.Sh., et al., 2009. A retrospective analysis of the efficacy of traditional Chinese and Western medicine in the treatment of children with chronic cell-immune thrombocytopenia purpura. Chinese Journal of Integrated Traditional Chinese and Western Medicine. 39(1), 48-51. [43] Yang, X.Q., Yu, H.P., Liu, Sh.F., et al., 2009. Clinical efficacy and observation of Fuzheng Tiaojing Jiedu Decoction in the treatment of children with purpura immune thrombocytopenia. Chinese Journal of Modern Pediatrics. 6, 30-34. [44] Huang, Zh.H., Ma, X.H., 2017. Clinical efficacy and analysis of Liangxue Huoxue Zhuxiaoyu Zhixue Tang Injection in the treatment of mice with primary immune thrombocytopenia purpura. Journal of Clinical Pharmacy and Molecular Experimental Biomedicine. 16(9), 886-889. [45] Ji, F., Xiao, H.Y., Hu, X.M., et al., 2016. Clinical and clinical study on the treatment of primary thrombocytopenic purpura with hormone contraceptive ineffective by nourishing Yin and supplementing qi and strengthening Yang. Shizhen Traditional Chinese Medicine. 7(1), 131-133. [46] Sun, Sh.J., Zhang, Y.L., Sun, F., et al. Effect of Qingrezaoshixiao Schonlein Prescription on autoimmune thrombocytopenia triad and its effect on serum IL-10 and TGF-β1 receptor. Sichuan Traditional Chinese Medicine. 19(37), 68-71. [47] Wang, T., Ding, Y., 2019. Sanqi Decoction for Invigorating spleen and invigorating Dampness and Yiqi and its biochemical effects on plasma T small cell subsets in patients with primary Qi, Yin and blood deficiency and chronic cell-immune thrombocytopenia triad. New Traditional Chinese Medicine. (5), 44-46. [48] Qiu, Y.Y., Chen, J., 2019. Effects of huoxue Tongluo Decoction combined with Chemotherapy on serum immune cytokines, platelet parameters and bone marrow metabolism in children with secondary thrombocytopenic purpura. World Traditional Chinese Medicine. 14(3), 674-678.